PL330637A1 - Agent for and method of treating hypostatic cardiac insufficiency - Google Patents

Agent for and method of treating hypostatic cardiac insufficiency

Info

Publication number
PL330637A1
PL330637A1 PL97330637A PL33063797A PL330637A1 PL 330637 A1 PL330637 A1 PL 330637A1 PL 97330637 A PL97330637 A PL 97330637A PL 33063797 A PL33063797 A PL 33063797A PL 330637 A1 PL330637 A1 PL 330637A1
Authority
PL
Poland
Prior art keywords
hypostatic
treating
agent
cardiac insufficiency
insufficiency
Prior art date
Application number
PL97330637A
Inventor
John L Mcnay
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL330637A1 publication Critical patent/PL330637A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL97330637A 1996-06-06 1997-06-05 Agent for and method of treating hypostatic cardiac insufficiency PL330637A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06
PCT/US1997/009914 WO1997046241A1 (en) 1996-06-06 1997-06-05 Formulation and method for treating congestive heart failure

Publications (1)

Publication Number Publication Date
PL330637A1 true PL330637A1 (en) 1999-05-24

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97330637A PL330637A1 (en) 1996-06-06 1997-06-05 Agent for and method of treating hypostatic cardiac insufficiency

Country Status (17)

Country Link
EP (1) EP0914128A1 (en)
JP (1) JP2000511906A (en)
KR (1) KR20000016406A (en)
CN (1) CN1226166A (en)
AU (1) AU3233197A (en)
BR (1) BR9709546A (en)
CA (1) CA2256720A1 (en)
CZ (1) CZ397698A3 (en)
EA (1) EA199900006A1 (en)
HU (1) HUP0003885A2 (en)
IL (1) IL126966A0 (en)
NO (1) NO985695L (en)
PL (1) PL330637A1 (en)
TR (1) TR199802496T2 (en)
WO (1) WO1997046241A1 (en)
YU (1) YU55998A (en)
ZA (1) ZA974978B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (en) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenesis stimulant comprising moxonidine, useful e.g. for treating hypothermia or promoting weight loss, having no cardiac stimulant side effects
WO2000044355A1 (en) * 1999-01-29 2000-08-03 Eli Lilly And Company Moxonidine salts
NZ513869A (en) 1999-02-01 2001-09-28 Solvay Pharm Gmbh Use of moxonidine for postmyocardial infarction treatment
DE602006018139D1 (en) * 2006-08-31 2010-12-23 Chemagis Ltd Use of the monoxidine salts to purify monoxide
KR100812287B1 (en) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 Shade for a traffic signal lamp having reflective layer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (en) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermal drug
DE3729299A1 (en) * 1987-09-02 1989-03-23 Beiersdorf Ag TRANSDERMAL THERAPEUTIC SYSTEM
DE3904795C2 (en) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmaceutical preparation and its use
DE4325491A1 (en) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Use of centrally acting alpha-2 agonists to inhibit post-aggression metabolism
DE4423177A1 (en) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglycemic drugs
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal

Also Published As

Publication number Publication date
CZ397698A3 (en) 1999-05-12
IL126966A0 (en) 1999-09-22
HUP0003885A2 (en) 2001-04-28
EP0914128A1 (en) 1999-05-12
NO985695D0 (en) 1998-12-04
EA199900006A1 (en) 1999-06-24
WO1997046241A1 (en) 1997-12-11
BR9709546A (en) 1999-08-10
CA2256720A1 (en) 1997-12-11
TR199802496T2 (en) 1999-02-22
YU55998A (en) 1999-11-22
JP2000511906A (en) 2000-09-12
ZA974978B (en) 1998-12-07
NO985695L (en) 1999-02-04
KR20000016406A (en) 2000-03-25
CN1226166A (en) 1999-08-18
AU3233197A (en) 1998-01-05

Similar Documents

Publication Publication Date Title
EP1007152A4 (en) Method and apparatus for treating cardiac arrhythmia
IL128545A0 (en) Method for treating and preventing heart failure and ventricular dilatation
PL317930A1 (en) Oxalydine compounds, method of obtaining them and therapeutic agents
EP0740566A4 (en) Method and apparatus for uniform radiation treatment of vascular lumens
EP1022945A4 (en) Method and formulation for treating vascular disease
EP0973461A4 (en) Method of treatment of migraine
PL313433A1 (en) Derivatives of benzazepin-, benzoxazepin- and benzothiazepin-n-acetic acids, method of obtaining them and therapeutic agents containing such derivatives
PL320952A1 (en) Cycloalkanon pyridines, method of obtaining and therapeutic agents containing them
IL129272A0 (en) Method and composition for treating skin damage
PL321201A1 (en) Derivatives of 4-hydroxypiepridine, method of obtaining them and therapeutic agents containing such derivatives
ZA977564B (en) Method of treatment
PL307669A1 (en) Benzimidazoles, therapeutic agents containing them and method of obtaining such compounds
EP1014972A4 (en) Method of treatment and pharmaceutical composion
GB2328008B (en) Method of heat treating object and apparatus for the same
EP0735054A3 (en) Method of after treatment of modified polyolefins
PL321587A1 (en) Bonding agent and method of obtaining same
PL330637A1 (en) Agent for and method of treating hypostatic cardiac insufficiency
EP0938296A4 (en) Method of treating alopecia
PL306093A1 (en) Cataract treating agent and method of obtaining same
EP1009433A4 (en) Therapeutic composition and method of treatment
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
EP1007145A4 (en) Blood evacuating system and method of use thereof
EP0763143A4 (en) Method of treating titanium parts
EG20694A (en) Process for treatment of afluid and apparatus therefor